Literature DB >> 18729533

Local treatment of vulvovaginal candidosis : general and practical considerations.

José das Neves1, Eugénia Pinto, Branca Teixeira, Gustavo Dias, Patrocínia Rocha, Teresa Cunha, Bárbara Santos, Maria H Amaral, Maria F Bahia.   

Abstract

Vulvovaginal candidosis is a common worldwide female medical problem, occurring mostly in women of childbearing age. Currently available options for the treatment of this condition include local and oral (systemic) therapy. Both alternatives have been considered equally effective in the treatment of uncomplicated vulvovaginal candidosis, although oral regimens are often preferred by physicians and women. However, local treatment presents several advantageous and unique features that may favour this therapeutic approach. The availability of numerous antifungal drugs and products for topical administration makes the selection quite challenging as this task is mostly based on personal experience or anecdotal data. Also, recent advances have been made in topical antifungal formulations and there is an increasing availability of over-the-counter products. Therefore, a review of both general and practical considerations related to the local treatment of vulvovaginal candidosis is timely.In summary, azoles and short-term regimens are usually recommended for the local treatment of vulvovaginal candidosis, with nystatin and boric acid considered as second-line alternatives. Unconventional approaches may also be regarded as suitable in patients refractory to usual treatments. In addition to the susceptibility of implicated Candida spp. to the antifungal agents, this choice should take into consideration other important issues such as particular situations (e.g. pregnancy, menopause, drug hypersensitivity), women's preferences, and the availability, particularities and cost of antifungal formulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729533     DOI: 10.2165/00003495-200868130-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  96 in total

1.  Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model.

Authors:  David A Stevens; Leilani Calderon; Martha Martinez; Karl V Clemons; Shelly J Wilson; Claude P Selitrennikoff
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

Review 2.  Gels as vaginal drug delivery systems.

Authors:  J das Neves; M F Bahia
Journal:  Int J Pharm       Date:  2006-03-17       Impact factor: 5.875

3.  Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.

Authors:  Debarti Ray; Ravinder Goswami; Uma Banerjee; Vatsla Dadhwal; Deepti Goswami; Piyali Mandal; Vishnubhatla Sreenivas; Narayana Kochupillai
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

4.  Association between atopy and recurrent vaginal candidiasis.

Authors:  N A Neves; L P Carvalho; M A M De Oliveira; P C Giraldo; O Bacellar; A A Cruz; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.

Authors:  D Brown; M R Henzl; R H Kaufman
Journal:  J Reprod Med       Date:  1999-11       Impact factor: 0.142

6.  Polysorbate 80 hypersensitivity.

Authors:  W B Shelley; N Talanin; E D Shelley
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

7.  Safety and efficacy of bedtime versus daytime administration of the miconazole nitrate 1200 mg vaginal ovule insert to treat vulvovaginal candidiasis.

Authors:  Kurt Barnhart
Journal:  Curr Med Res Opin       Date:  2005-01       Impact factor: 2.580

8.  Antimicrobial activity of essential oils and other plant extracts.

Authors:  K A Hammer; C F Carson; T V Riley
Journal:  J Appl Microbiol       Date:  1999-06       Impact factor: 3.772

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.

Authors:  Larry S Seidman; Campbell K Skokos
Journal:  Infect Dis Obstet Gynecol       Date:  2005-12
View more
  9 in total

1.  Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care.

Authors:  Isabel Del-Cura González; Francisca García-de-Blas González; Teresa Sanz Cuesta; Jesús Martín Fernández; Justo M Del-Alamo Rodríguez; Rosa A Escriva Ferrairo; M Del Canto De-Hoyos Alonso; Laura Balsalobre Arenas; Ricardo Rodríguez Barrientos; Elisa Ceresuela Wiesmann; Cristina De-Alba Romero; Yolanda Ginés Díaz; Ana Pastor Rodríguez-Moñino; Blanca Gutiérrez Teira; Marta Sánchez-Celaya Del Pozo; Jesús Fernández Horcajuelo; María J Rojas Giraldo; Paulino Cubero González; Rocío A Vello Cuadrado; Beatriz López Uriarte; Jeannet Sánchez Yepes; Yolanda Hernando Sanz; M José Iglesias Piñeiro; Susana Tudanca Hernández; Fernando Gallardo Alonso; Ana I González González; Alicia Simón Fernández; Carmen Carballo; Ana Rey López; Fernanda Morales; Dolores Martínez López
Journal:  BMC Public Health       Date:  2011-01-31       Impact factor: 3.295

Review 2.  Vaginal yeast infections during pregnancy.

Authors:  Derrick Soong; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2009-03       Impact factor: 3.275

3.  In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.

Authors:  Cristina Marcos-Arias; Elena Eraso; Lucila Madariaga; Alfonso Javier Carrillo-Muñoz; Guillermo Quindós
Journal:  Mycopathologia       Date:  2011-08-14       Impact factor: 2.574

4.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

5.  Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.

Authors:  Stavroula Antonopoulou; Michel Aoun; Evangelos C Alexopoulos; Stavroula Baka; Emanuel Logothetis; Theodoros Kalambokas; Andreas Zannos; Konstantine Papadias; Odysseas Grigoriou; Evangelia Kouskouni; Aristea Velegraki
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

6.  Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.

Authors:  Diego C Rossi; Julian E Muñoz; Danielle D Carvalho; Rodrigo Belmonte; Bluma Faintuch; Primavera Borelli; Antonio Miranda; Carlos P Taborda; Sirlei Daffre
Journal:  BMC Microbiol       Date:  2012-03-06       Impact factor: 3.605

7.  Determination of Antibacterial and Technological Properties of Vaginal Lactobacilli for Their Potential Application in Dairy Products.

Authors:  Lorenzo Siroli; Francesca Patrignani; Diana I Serrazanetti; Carola Parolin; Rogers A Ñahui Palomino; Beatrice Vitali; Rosalba Lanciotti
Journal:  Front Microbiol       Date:  2017-02-07       Impact factor: 5.640

8.  Polymeric films as a promising carrier for bioadhesive drug delivery: Development, characterization and optimization.

Authors:  Pallavi Bassi; Gurpreet Kaur
Journal:  Saudi Pharm J       Date:  2015-06-25       Impact factor: 4.330

9.  Use of Lactobacillus crispatus to produce a probiotic cheese as potential gender food for preventing gynaecological infections.

Authors:  Francesca Patrignani; Lorenzo Siroli; Carola Parolin; Diana I Serrazanetti; Beatrice Vitali; Rosalba Lanciotti
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.